Effect of Open-Label Placebos on Weight Loss and Hunger in Obesity

Effect of Open-Label Placebos on Weight Loss and Hunger in Obesity - PLOBE2

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00036915

Enrollment

180

Registered

2025-05-15

Start date

2025-06-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E66

Interventions

Group 1: Intervention group 1 will receive an open-label placebo twice daily for 4 weeks. Group 2: Intervention group 2 will receive a concealed placebo twice daily for 4 weeks. Group 3: Control group

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: BMI > 25

Exclusion criteria

Exclusion criteria: No known history of psychiatric, neurological, or endocrine disorders, or eating disorders (assessed via self-report)

Design outcomes

Primary

Measure	Time frame
Weight and eating behavior (assessed using the FEV) will be measured at baseline, after 4 weeks, 8 weeks, and 6 months.	—

Secondary

Measure	Time frame
The Questionnaire for the Assessment of Resources and Self-Management Skills (FERUS), body fat percentage, and waist-to-hip ratio will be measured at baseline and after 4 weeks.	—

Countries

Germany

Contacts

Public ContactMichael Schaefer

Medical School Berlin

michael.schaefer@medicalschool-berlin.de+49 (0) 306117542

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026